Founded in 2008, Castle Biosciences is a leading molecular diagnostics company focused on improving health through innovative tests that guide patient care. Realizing a large unmet clinical need in disease management, we continuously strive to evolve and improve, challenging the status quo with scientific expertise, value insights and robust data development.

Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing clinicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. The TissueCypher® Barrett’s Esophagus test is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix® is a pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient.

With an estimated U.S. Total Addressable Market (TAM) of approximately $8 billion for our commercially available tests and an additional estimated $5.7 billion market potential through our pipeline initiatives, we are well positioned to capitalize on the significant market opportunities available to us.

Corporate Presentation

Upcoming Events

View All Events

Quarterly Results

View All Financial Results


View all news

Annual Report

2022 was a year of significant growth and success for Castle, driven by strong execution and our steadfast commitment to improve patient care through our innovative, actionable tests.

We delivered strong year-over-year growth in revenue and test report volume, reflecting solid execution by our Castle team. Our full-year 2022 revenue increased by 46% over 2021 to $137 million, meeting the top end of our guided range. Download PDF